Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Today, 6:15 AMSanofi says AI-enabled development of asthma drug lunsekimig saved at least a year and allowed it to skip a dose-selection study.
Index
-
Market Cap
111.46B
Enterprise Value
131.56B
Income
4.69B
Sales
53.47B
Book/sh
32.59
Cash/sh
3.05
Employees
76493
IPO
Jul 01, 2002
P/E
24.08
Forward P/E
8.83
PEG
1.21
P/S
2.08
P/B
1.44
P/C
15.35
P/FCF
9.25
EV/EBITDA
5.85
EV/Sales
2.46
Quick Ratio
0.64
Current Ratio
0.99
Debt/Eq
0.34
LT Debt/Eq
0.24
Option/Short
Yes / Yes
EPS (ttm)
1.94
EPS next Y
5.29
EPS next Q
0.91
EPS this Y
6.11%
EPS next Y
6.83%
EPS next 5Y
7.32%
EPS past 3/5Y
-11.86% -15.52%
Sales past 3/5Y
2.90% 3.69%
EPS Y/Y TTM
-30.90%
Sales Y/Y TTM
23.68%
EPS Q/Q
-32.22%
Sales Q/Q
18.71%
Insider Own
0.00%
Insider Trans
-
Inst Own
7.47%
Inst Trans
-0.82%
ROA
3.12%
ROE
5.70%
ROIC
4.80%
Gross Margin
66.29%
Oper. Margin
27.17%
Profit Margin
8.78%
SMA20
1.31%
SMA50
8.54%
SMA200
5.43%
Trades
Shs Outstand
2.43B
Shs Float
2.38B
52W High
50.60 -7.59%
52W Low
39.07 19.69%
Volatility
1.68% 1.88%
ATR (14)
1.01
RSI (14)
58.78
Beta
0.24
Rel Volume
1.09
Avg Volume
3.35M
Volume
2,766,370
Perf Week
-3.32%
Perf Month
11.44%
Perf Quarter
2.35%
Perf Half Y
5.58%
Perf YTD
-3.50%
Perf Year
-4.35%
Perf 3Y
0.56%
Perf 5Y
-7.15%
Perf 10Y
17.44%
Prev Close
46.06
Price
46.76
Change %
1.52%
Consensus
Buy
Avg. Price Target
$52.56
Implied Upside
+12.4%
Analysts14incl. previous ratings
Rating Distribution4 Buy · 10 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 09, 2026Upgrade
BBNP Paribas Exane
Neutral → Outperform$57+21.9%
Oct 09, 2026Initiated
WWolfe Research
Peer Perform
Sep 09, 2026Initiated
RY logoRRBC Capital Mkts
Sector Perform
May 01, 2026Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight
Apr 20, 2026Downgrade
BBNP Paribas Exane
Outperform → Neutral$50+6.9%
Feb 12, 2026Downgrade
BAC logoBBofA Securities
Buy → Neutral
Jan 27, 2026Initiated
C logoCCitigroup
Neutral
Jan 16, 2026Downgrade
UBS logoUUBS
Buy → Neutral
Jan 06, 2026Downgrade
BCS logoBBarclays
Overweight → Equal Weight
Dec 09, 2025Downgrade
GGuggenheim
Buy → Neutral
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines, vaccines franchises, support, and corporate functions 1973 and is headquartered in Paris, France.
CEO & DirectorMs. Belen Garijo Lopez M.D.
Executive VP & CFOMr. Francois-Xavier Roger
Chief Scientific Officer & Head of ResearchDr. Michael Quigley Ph.D.
Head of Investor Relations & General MedicinesMr. Thomas Kudsk Larsen
Executive VP & General CounselMs. Jamie Haney